On Apr 3, Zacks Investment Research upgraded ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to Zacks Rank #1 (Strong Buy). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s loss estimates have declining on the back of better-than-expected fourth quarter 2013 results. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -6.06% in last session and finished the day at $4.34. Traded volume was 1.86million shares in the last session and the average volume of the stock remained 1.07million shares. The beta of the stock remained 2.40. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) insider ownership is 1.80%.

Sangamo Biosciences Inc (NASDAQ:SGMO) was the target of a significant increase in short interest during the month of January. As of March 14th, there was short interest totalling 11,166,388 shares, an increase of 24.8% from the February 28th total of 8,950,725 shares, Stock Ratings Network.com reports. Sangamo Biosciences, Inc. (NASDAQ:SGMO) dropped -5.21 percent to $16.75 Thursday on volume of 1.71million shares. The intra-day range of the stock was $15.91 to $17.64. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has a market capitalization of $1.12billion.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that Lexicon management will present at the Needham Healthcare Conference on Tuesday, April 8, 2014 at 9:20 AM EDT in New York City. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) management will provide an overview of Lexicon’s clinical development programs and milestones. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s stock on Apr 03, 2014 reported a decrease of -6.68% to the closing price of $1.69. Its fifty two weeks range is $1.62 -$3.18. The total market capitalization recorded $868.31million. The overall volume in the last trading session was 1.89million shares. In its share capital, LXRX has 513.82million outstanding shares.

According to XOMA Corp (NASDAQ:XOMA), it anticipates cash used in ongoing activities during 2014 to be c. $55.0 million to $60.0 million, primarily reflecting the costs associated with conducting the gevokizumab three Phase 3 clinical trials in the EYEGUARD program and the costs associated with conducting a Phase 3 clinical trial in patients with pyoderma gangrenosum. On Thursday, shares of XOMA Corp (NASDAQ:XOMA) dropped -6.11% to close the day at $4.92. Company return on investment (ROI) is -157.30% and its monthly performance is recorded as -27.86%. XOMA Corp (NASDAQ:XOMA) quarterly revenue growth is -28.90%.